OncoKB New Data Release - February 27, 2025
Contact OncoKB
Data Release v4.26
February 27, 2025
What's New
Update to our FDA-Approved Oncology Therapies page
Updated Therapeutic Implications:
Promotion of tumor type-specific level of evidence for an alteration
Level 2: FGFR2 and FGFR3 Oncogenic Mutations in non-small cell lung cancer promoted from Level 4 to Level 2 based on Non-Small Cell Lung Cancer NCCN Guideline V3.2025 inclusion of Erdafitinib for patients with FGFR-mutant non-small cell lung cancer (PMID: 37541273)
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 1: Addition of Encorafenib + Cetuximab + FOLFOX Regimen to BRAF V600E in colorectal cancer based on FDA approval of encorafenib with cetuximab and mFOLFOX6 in BRAF V600E-mutated colorectal cancer (PMID: 39863775)
Level 1 sensitivity-associated evidence currently in OncoKB™ for BRAF V600E in colorectal cancer: Encorafenib + Cetuximab
Gene Curation:
Addition of 8 new genes:
ALOX5 APEX1 CBLB DHX15 POLH RPS6KB1 TACSTD2 WEE1
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
